The global cell analysis market was valued at an estimated $34.3 billion in 2025 and is projected to reach $81.0 billion by 2033, according to a report added to ResearchAndMarkets.com's offering. The market is forecast to expand at a compound annual growth rate of 11.7% from 2026 to 2033, driven by the increasing prevalence of chronic diseases, advances in cell analysis technologies and rising investment in drug discovery and therapeutic development. Cell analysis applications span oncology, early cancer diagnostics, biomarker identification, treatment selection, targeted therapy development, research tools and precision treatment strategies. The 120-page report provides revenue estimates and forecasts from 2021 to 2033 across product and service categories, techniques, processes, end-use sectors and regions. It covers North America, Europe, Asia Pacific, Latin America and MEA, with country-level analysis across 23 markets. The competitive review profiles Thermo Fisher Scientific, Danaher, BD, Merck KGaA, Agilent Technologies, Bio-Rad Laboratories, Miltenyi Biotech, Revvity, New England Biolabs and Avantor.